Loading...

This dashboard visualizes key Quality of Life (QoL) outcomes from the MONALEESA-3 study comparing Ribociclib + Fulvestrant vs. Placebo + Fulvestrant in advanced breast cancer.

Study Design & Arms

Baseline Quality of Life Scores (Mean ± SD)

Comparison of baseline scores for Global Health Status and Pain. Error bars represent Standard Deviation.

Time to Definitive Deterioration (Median Months)

Median months until ≥10% deterioration in QoL scores. Higher is better (longer time to deterioration).

Hazard Ratios for Deterioration (Forest Plot)

Hazard Ratio (HR) < 1 favors Ribociclib + Fulvestrant. Error bars indicate 95% Confidence Intervals.

Effect Direction Summary

Overview of which arm is favored across all TTD metrics.

Metric Explorer

Appendix: Raw Data & Sources